Review




Structured Review

AstraZeneca ltd gitrl-fp antibody
Gitrl Fp Antibody, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/amp+224/pmc09398146-55-12-15
Average 90 stars, based on 1 article reviews
gitrl-fp antibody - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

other:

Article Title: C
Article Snippet: PD-1 inhibitors that blocks the interaction of PD-1 and PD-L1 by binding to the PD-1 receptor, and in turn inhibit immune suppression include, for example, nivolumab (Opdivo), pembrolizumab (Keytruda), pidilizumab, AMP-224 (AstraZeneca and MedImmune), PF-06801591 (Pfizer), MEDI680 (AstraZeneca), PDR001 (Novartis), REGN2810 (Regeneron), SHR-12-1 (Jiangsu Hengrui Medicine Company and Incyte Corporation), TSR-042 (Tesaro), and the PD-L1/VISTA inhibitor CA-170 (Curis Inc.).

Article Title: Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
Article Snippet: For example, the anti-PD-1 antibody used in accordance with the present invention may be selected from those disclosed in Ohaegbulam et al. (Ohaegbulam et al, 2015), the entire contents of which being hereby incorporated herein by reference, i.e. CT-011 (pidilizumab; Humanized IgG1; Curetech), MK-3475 (lambrolizumab, pembrolizumab; Humanized IgG4; Merck), BMS-936558 (nivolumab; Human IgG4; Bristol-Myers Squibb), AMP-224 (PD-L2 IgG2a fusion protein; AstraZeneca), BMS-936559 (Human IgG4; Bristol-Myers Squibb), MEDI4736 (Humanized IgG; AstraZeneca), MPDL3280A (Human IgG; Genentech), MSB0010718C (Human IgG1; Merck-Serono); or the antibody used in accordance with the present invention may be MEDI0680 (AMP-514; AstraZeneca) a humanized IgG4 mAb.

Article Title: Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
Article Snippet: For example, the anti-PD-1 antibody used in accordance with the present invention may be selected from those disclosed in Ohaegbulam et al. (Ohaegbulam et al, 2015), the entire contents of which being hereby incorporated herein by reference, i.e. CT-011 (pidilizumab; Humanized IgG1; Curetech), MK-3475 (lambrolizumab, pembrolizumab; Humanized IgG4; Merck), BMS-936558 (nivolumab; Human IgG4; Bristol-Myers Squibb), AMP-224 (PD-L2 IgG2a fusion protein; AstraZeneca), BMS-936559 (Human IgG4; Bristol-Myers Squibb), MEDI4736 (Humanized IgG; AstraZeneca), MPDL3280A (Human IgG; Genentech), MSB0010718C (Human IgG1; Merck-Serono); or the antibody used in accordance with the present invention may be MEDI0680 (AMP-514; AstraZeneca) a humanized IgG4 mAb.

Article Title: Benzothiophene-based selective estrogen receptor downregulator compounds
Article Snippet: In one embodiment, the checkpoint inhibitor is a PD-1 checkpoint inhibitor selected from nivolumab, pembrolizumab, pidilizumab, AMP-224 (AstraZeneca and MedImmune), PF-06801591 (Pfizer), MEDI0680 (AstraZeneca), PDR001 (Novartis), REGN2810 (Regeneron), SHR-12-1 (Jiangsu Hengrui Medicine Company and Incyte Corporation), TSR-042 (Tesaro), and the PD-L1/VISTA inhibitor CA-170 (Curis Inc.).

Article Title: Peptide-containing linkers for antibody-drug conjugates
Article Snippet: Exemplary antibodies against PD-1 include: Anti-mouse PD-1 antibody Clone J43 (Cat #BE0033-2) from BioXcell; Anti-mouse PD-1 antibody Clone RMP1-14 (Cat #BE0146) from BioXcell; mouse anti-PD-1 antibody Clone EH12; Merck's MK-3475 anti-mouse PD-1 antibody (Keytruda®, pembrolizumab, lambrolizumab, h409A11); and AnaptysBio's anti-PD-1 antibody, known as ANB011; antibody MDX-1 106 (ONO-4538); Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106); AstraZeneca's AMP-514, and AMP-224; and Pidilizumab (CT-011 or hBAT-1), CureTech Ltd. Additional exemplary anti-PD-1 antibodies are described by Goldberg et al, Blood 1 10(1): 186-192 (2007), Thompson et al, Clin.

Article Title: Breast and ovarian cancer vaccines
Article Snippet: Exemplary checkpoint inhibitors include: PD-L1 inhibitors such as Genentech's MPDL3280A (RG7446), Anti-mouse PD-L1 antibody Clone 10F.9G2 (Cat #BE0101) from BioXcell, anti-PD-L1 monoclonal antibody MDX-1105 (BMS-936559) and BMS-935559 from Bristol-Meyer's Squibb, MSB0010718C, mouse anti-PD-L1 Clone 29E.2A3, and AstraZeneca's MEDI4736; PD-L2 inhibitors such as GlaxoSmithKline's AMP-224 (Amplimmune), and rHIgM12B7; PD-1 inhibitors such as anti-mouse PD-1 antibody Clone J43 (Cat #BE0033-2) from BioXcell, anti-mouse PD-1 antibody Clone RMP1-14 (Cat #BE0146) from BioXcell, mouse anti-PD-1 antibody Clone EH12, Merck's MK-3475 anti-mouse PD-1 antibody (Keytruda, pembrolizumab, lambrolizumab), AnaptysBio's anti-PD-1 antibody known as ANB011, antibody MDX-1 106 (ONO-4538), Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106), AstraZeneca's AMP-514 and AMP-224, and Pidilizumab (CT-011) from CureTech Ltd; CTLA-4 inhibitors such as Bristol Meyers Squibb's anti-CTLA-4 antibody ipilimumab (also known as Yervoy®, MDX-010, BMS-734016 and MDX-101), anti-CTLA4 Antibody, clone 9H10 from Millipore, Pfizer's tremelimumab (CP-675,206, ticilimumab), and anti-CTLA4 antibody clone BNI3 from Abcam; LAG3 inhibitors such as anti-Lag-3 antibody clone eBioC9B7W (C9B7W) from eBioscience, anti-Lag3 antibody LS-B2237 from LifeSpan Biosciences, IMP321 (ImmuFact) from Immutep, anti-Lag3 antibody BMS-986016, and the LAG-3 chimeric antibody A9H12; B7-H3 inhibitors such as MGA271; KIR inhibitors such as Lirilumab (IPH2101); CD137 inhibitors such as urelumab (BMS-663513, Bristol-Myers Squibb), PF-05082566 (anti-4-1BB, PF-2566, Pfizer), or XmAb-5592 (Xencor); PS inhibitors such as Bavituximab; and inhibitors such as an antibody or fragments (e.g., a monoclonal antibody, a human, humanized, or chimeric antibody) thereof, RNAi molecules, or small molecules to TIM3, CD52, CD30, CD20, CD33, CD27, OX40, GITR, ICOS, BTLA (CD272), CD160, 2B4, LAIR1, TIGHT, LIGHT, DR3, CD226, CD2, or SLAM.

Article Title: Combination therapies with Cbl-b inhibitor compounds
Article Snippet: In certain embodiments, the PD-1 axis antagonist is selected from the group consisting of JTX-4014 (Jounce Therapeutics); spartalizumab (PDR001; Novartis); Camrelizumab (SHR1210; Jiangsu HengRui Medicine Co., Ltd); sintilimab (IBI308; Innovent and Eli Lilly); tislelizumab (BGB-A317; Novartis); toripalimab (JS 001; Coherus); Dostarlimab (TSR-042, WBP-285; GlaxoSmithKline); INCMGA00012 (MGA012; Incyte and MacroGenics); AMP-224 (AstraZeneca/MedImmune and GlaxoSmithKline); and AMP-514 (MEDI0680; AstraZeneca).

Article Title: Nucleic acid-polypeptide compositions and uses thereof
Article Snippet: In some embodiments, exemplary checkpoint inhibitors include: PD-L1 inhibitors such as Genentech's MPDL3280A (RG7446), Anti-mouse PD-L1 antibody Clone 10F.9G2 (Cat #BE0101) from BioXcell, anti-PD-L1 monoclonal antibody MDX-1105 (BMS-936559) and BMS-935559 from Bristol-Meyer's Squibb, MSB0010718C, mouse anti-PD-L1 Clone 29E.2A3, and AstraZeneca's MEDI4736; PD-L2 inhibitors such as GlaxoSmithKline's AMP-224 (Amplimmune), and rHIgM12B7; PD-1 inhibitors such as anti-mouse PD-1 antibody Clone J43 (Cat #BE0033-2) from BioXcell, anti-mouse PD-1 antibody Clone RMP1-14 (Cat #BE0146) from BioXcell, mouse anti-PD-1 antibody Clone EH12, Merck's MK-3475 anti-mouse PD-1 antibody (Keytruda, pembrolizumab, lambrolizumab), AnaptysBio's anti-PD-1 antibody known as ANB011, antibody MDX-1 106 (ONO-4538), Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106), AstraZeneca's AMP-514 and AMP-224, and Pidilizumab (CT-011) from CureTech Ltd; CTLA-4 inhibitors such as Bristol Meyers Squibb's anti-CTLA-4 antibody ipilimumab (also known as Yervoy®, MDX-010, BMS-734016 and MDX-101), anti-CTLA4 Antibody, clone 9H10 from Millipore, Pfizer's tremelimumab (CP-675,206, ticilimumab), and anti-CTLA4 antibody clone BNI3 from Abcam; LAG3 inhibitors such as anti-Lag-3 antibody clone eBioC9B7W (C9B7W) from eBioscience, anti-Lag3 antibody LS-B2237 from LifeSpan Biosciences, IMP321 (ImmuFact) from Immutep, anti-Lag3 antibody BMS-986016, and the LAG-3 chimeric antibody A9H12; B7-H3 inhibitors such as MGA271; KIR inhibitors such as Lirilumab (IPH2101); CD137 (41BB) inhibitors such as urelumab (BMS-663513, Bristol-Myers Squibb), PF-05082566 (anti-4-1BB, PF-2566, Pfizer), or XmAb-5592 (Xencor); PS inhibitors such as Bavituximab; and inhibitors such as an antibody or fragments (e.g., a monoclonal antibody, a human, humanized, or chimeric antibody) thereof, RNAi molecules, or small molecules to TIM3, CD52, CD30, CD20, CD33, CD27, OX40 (CD134), GITR, ICOS, BTLA (CD272), CD160, 2B4, LAIR1, TIGHT, LIGHT, DR3, CD226, CD2, or SLAM.



Similar Products

90
AstraZeneca ltd medi1873 hexameric gitrl fusion protein (gitrl fp)
Structure of GITR agonists being evaluated in ongoing or completed clinical trials
Medi1873 Hexameric Gitrl Fusion Protein (Gitrl Fp), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/medi1873/pmc10278658-11-16-2
Average 90 stars, based on 1 article reviews
medi1873 hexameric gitrl fusion protein (gitrl fp) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd mouse glucocorticoid-induced tnfr-related protein ligand-fusion protein (gitrl-fp) migg2a
Structure of GITR agonists being evaluated in ongoing or completed clinical trials
Mouse Glucocorticoid Induced Tnfr Related Protein Ligand Fusion Protein (Gitrl Fp) Migg2a, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/mouse+glucocorticoid+induced+tnfr+related+protein+ligand+fusion+protein++gitrl+fp++migg2a/pmc08215240-41-12-17
Average 90 stars, based on 1 article reviews
mouse glucocorticoid-induced tnfr-related protein ligand-fusion protein (gitrl-fp) migg2a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd gitrl-fp antibody
Structure of GITR agonists being evaluated in ongoing or completed clinical trials
Gitrl Fp Antibody, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/amp+224/pmc09398146-55-12-15
Average 90 stars, based on 1 article reviews
gitrl-fp antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd gitrl-fp (mouse igg2a
Structure of GITR agonists being evaluated in ongoing or completed clinical trials
Gitrl Fp (Mouse Igg2a, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/amp+224/10__1158_slash_1535___7163__mct___20___0902-181-9-12
Average 90 stars, based on 1 article reviews
gitrl-fp (mouse igg2a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedImmune llc gitrl-fp
Structure of GITR agonists being evaluated in ongoing or completed clinical trials
Gitrl Fp, supplied by MedImmune llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/gitrl+fp/pm28649380-19-1-14
Average 90 stars, based on 1 article reviews
gitrl-fp - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedImmune llc mouse gitr ligand fusion protein (gitrl fp)
Structure of GITR agonists being evaluated in ongoing or completed clinical trials
Mouse Gitr Ligand Fusion Protein (Gitrl Fp), supplied by MedImmune llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/mouse+gitr+ligand+fusion+protein++gitrl+fp+/pm28283653-39-8-18
Average 90 stars, based on 1 article reviews
mouse gitr ligand fusion protein (gitrl fp) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Thermo Fisher gitrl fp protein
Structure of GITR agonists being evaluated in ongoing or completed clinical trials
Gitrl Fp Protein, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gitrl-fp/gitrl+fp+protein/10__1080_slash_2162402x__2017__1280645-34-0-30
Average 90 stars, based on 1 article reviews
gitrl fp protein - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Structure of GITR agonists being evaluated in ongoing or completed clinical trials

Journal: Oncotarget

Article Title: Targeting GITR in cancer immunotherapy – there is no perfect knowledge

doi: 10.18632/oncotarget.28461

Figure Lengend Snippet: Structure of GITR agonists being evaluated in ongoing or completed clinical trials

Article Snippet: MEDI1873 , AstraZeneca , Hexameric GITRL fusion protein (GITRL FP) comprising 2 GITRL ECD trimers and IgG1 Fc linked by isoleucine zipper trimerization domain , Fully human IgG1 , Yes , Hexavalent.

Techniques: Binding Assay